Few Asymptomatic Pancreatic Cancers Successfully Detected By Genetic Test – ZMR Blog
Trending News & Updates

Few Asymptomatic Pancreatic Cancers Successfully Detected By Genetic Test

Few Asymptomatic Pancreatic Cancers Successfully Detected By Genetic Test

A research team at the UPMC has developed a genetic test that proved to be extremely sensitive at recognizing which pancreatic cysts are most probable to be related to one of the most aggressive sorts of pancreatic cancer. The successful outcomes are a vital step forward to the approach of precision medicine to analyze and treat pancreatic cancer.

Pancreatic cysts—tiny fluid pockets in the pancreas—are progressively discovered on medical scans by coincidence; mostly, they are benign. But as few can advance to pancreatic cancer, the physicians must find out whether it is surgically essential to take out the cysts.

PancreaSeq® developed by the team needs removing small fluid volumes from the cyst to test for a set of 10 diverse tumor genes linked to pancreatic cancer. This was foremost such prospective research, analyzing pancreatic cysts prior to surgery instead of examining cysts post-surgery.

The research was also foremost to assess a test that used a more sensitive genetic sequencing technique known as next-generation sequencing and the initial to be executed in an accredited and certified clinical laboratory rather than a research setting.

genetic test pancreatic cancers

The test, in this study phase, was not proposed to be utilized as the only factor in finding out whether to take out the cyst or not, so physicians depended on existing guidelines when settling on a treatment course. Overall, 595 patients were analyzed and the researchers followed up with examination of surgically detached cysts, obtainable for 102 patients, to estimate the test’s accuracy.

The study demonstrated that with an accuracy of 100%, PancreaSeq aptly distinguished every patient in the assessment group who had IPMN (intraductal papillary mucinous neoplasm)—a common predecessor to pancreatic cancer—on the basis of the existence of mutations in 2 genes, GNAS and KRAS. Additionally, by scrutinizing mutations in 3 extra genes, the assay also recognized the cysts that would ultimately advance to become cancerous lesions, with 100% accuracy as well. However, it was less precise for the less prevalent pancreatic cyst kind known as MCN (mucinous cystic neoplasm)—identifying only 30% of the cases. Notably, false positives were not recognized by PancreaSeq in any of the cyst types thereby, making it an extremely specific test.

As per mentioned by the team, an enhanced version of the PancreaSeq that integrates other tumor genes linked to pancreatic cancer, at present, is undergoing thorough clinical testing. In the future, the research team mentions, clinical guidelines will have to be revisited to investigate incorporating tests such as PancreaSeq.

Leave A Reply

Your email address will not be published.